Morphine and myocardial ischaemia-reperfusion

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Science

Background:

• Coronary heart disease (CHD) is a leading cause of death globally.
• Myocardial injury from ischemia-reperfusion underlies heart failure in CHD.
• Morphine, an opioid agonist, is used for pain relief and has shown potential in cardiovascular conditions.

Purpose of the Study:

• To review the cardioprotective effects of morphine.
• To examine morphine's impact on myocardial ischemia-reperfusion injury and heart failure models.
• To assess morphine's role in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI).

Main Methods:

• Literature review of studies on morphine's effects in animal models of myocardial ischemia-reperfusion and heart failure.
• Analysis of clinical data on STEMI patients receiving morphine before or during PCI.
• Brief description of relevant signaling pathways.

Main Results:

• Morphine demonstrates protective effects in animal models of myocardial ischemia-reperfusion and chronic heart failure.
• Morphine administration shows positive effects in STEMI patients undergoing pre-primary percutaneous coronary intervention (pre-PPCI) or PPCI.
• Involvement of specific signaling pathways in morphine's cardioprotection is noted.

Conclusions:

• Morphine exhibits significant cardioprotective properties against ischemia-reperfusion injury and heart failure.
• Morphine may be a beneficial adjunct therapy for STEMI patients undergoing PCI.
• Further research into morphine's mechanisms and clinical applications in cardiovascular disease is warranted.